NO20071579L - 4-Heteroarylmetylsubstituerte ftalazinonderivater - Google Patents

4-Heteroarylmetylsubstituerte ftalazinonderivater

Info

Publication number
NO20071579L
NO20071579L NO20071579A NO20071579A NO20071579L NO 20071579 L NO20071579 L NO 20071579L NO 20071579 A NO20071579 A NO 20071579A NO 20071579 A NO20071579 A NO 20071579A NO 20071579 L NO20071579 L NO 20071579L
Authority
NO
Norway
Prior art keywords
formula
crxry
optionally substituted
group
heteroarylmethyl
Prior art date
Application number
NO20071579A
Other languages
English (en)
Inventor
Niall Morrison Barr Martin
Graeme Cameron Murray Smith
Xiao-Ling Fan Cockcroft
Muhammad Hashim Javaid
Sylvie Gomez
Jr Vincent Ming Lai Loh
Stefano Forte
Keith Allan Menear
Ian Timothy William Matthews
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0419072.4A external-priority patent/GB0419072D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of NO20071579L publication Critical patent/NO20071579L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Forbindelse med formel (I) for anvendelse ved behandling av kreft eller andre sykdommer som lindres ved behandling av PARP, hvori: A og B sammen representerer en eventuelt substituert sammensmeltet aromatisk ring; X kan være NRx eller CRxRy; hvis X = NRx, da er n 1 eller 2, og hvis X = CRxRy, da er n l; Rx er valgt fra gruppen som består av H, eventuelt substituert C1-20alkyl, C5-20aryl, C3-20heterosyklyl, amido, tioamido, ester, acyl og sulfonylgrupper; Ry er valgt fra H, hydroksy, amino; eller Rx og Ry kan sammen danne en spiro-C3-7sykloalkyl eller heterosyklylgruppe; RC1 og RC2 er uavhengig valgt fra gruppen som består av hydrogen og C1-4alkyl, eller når X er CRxRy, kan RC1, RC2 , Rx og Ry, sammen med karbonatomene til hvilke de er bundet, danne en eventuelt substituert sammensmeltet aromatisk ring; R1 er valgt fra H og halo; og Het er valgt fra: (i) formel (i), hvori Y1 er valgt fra CH og N, Y2 er valgt fra CH og N, Y3 er valgt fra CH, CF og N, hvor kun en eller to av Y1, Y2 og Y3 kan være N; og (ii) formel (ii), hvor Q er 0 eller S. formel (I)
NO20071579A 2004-08-26 2007-03-26 4-Heteroarylmetylsubstituerte ftalazinonderivater NO20071579L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419072.4A GB0419072D0 (en) 2004-08-26 2004-08-26 Phthalazinone derivatives
US60495604P 2004-08-27 2004-08-27
PCT/GB2005/003343 WO2006021801A1 (en) 2004-08-26 2005-08-26 4-heteroarylmethyl substituted phthalazinone derivatives

Publications (1)

Publication Number Publication Date
NO20071579L true NO20071579L (no) 2007-05-29

Family

ID=35219560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071579A NO20071579L (no) 2004-08-26 2007-03-26 4-Heteroarylmetylsubstituerte ftalazinonderivater

Country Status (11)

Country Link
EP (1) EP1791827A1 (no)
JP (1) JP2008510783A (no)
KR (1) KR20070057859A (no)
AU (1) AU2005276229A1 (no)
BR (1) BRPI0514632A (no)
CA (1) CA2577191A1 (no)
IL (1) IL181408A0 (no)
MX (1) MX2007002318A (no)
NO (1) NO20071579L (no)
NZ (1) NZ553979A (no)
WO (1) WO2006021801A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2699038A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
EP2220073B1 (en) 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2010070032A1 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
DK2513093T3 (da) 2009-12-17 2014-09-29 Boehringer Ingelheim Int Nye CCR2 receptor antagonister og anvendelser deraf
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2012014221A1 (en) 2010-07-27 2012-02-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
KR101242572B1 (ko) * 2010-10-12 2013-03-19 한국화학연구원 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물
WO2012071684A1 (en) * 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
WO2012125521A1 (en) * 2011-03-14 2012-09-20 Eternity Bioscience Inc. Quinazolinediones and their use
JP5960253B2 (ja) 2011-05-31 2016-08-02 ニューゲン セラピューティクス， インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
CN102977040B (zh) * 2012-11-20 2015-06-03 浙江工业大学 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法
AP2015008439A0 (en) 2012-12-31 2015-05-31 Cadila Healthcare Ltd Substituted phthalazin-1(2H)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
ES2811098T3 (es) 2015-07-02 2021-03-10 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidin-1-il)(5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2hpirano-2-il) metilamino)pirimidin-4il) metanona
CN105384684B (zh) * 2015-12-16 2018-02-13 辽宁工程技术大学 一种2‑氰基‑6‑甲基吡啶的制备方法
EP3758695A4 (en) * 2018-02-28 2021-10-06 The Trustees Of The University Of Pennsylvania POLY (AD-RIBOSE) DEPENDENT CYTOTOXIC AGENTS LOW AFFINITY POLYMERASE-1
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2020155141A1 (zh) * 2019-02-02 2020-08-06 中国科学院上海有机化学研究所 治疗神经退行性疾病或rna结合蛋白发生异常导致的疾病的药物组合物及其应用
AU2020318599B2 (en) 2019-07-19 2023-09-07 Astrazeneca Ab PARP1 inhibitors
WO2021220120A1 (en) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
EP4320116A1 (en) 2021-04-08 2024-02-14 Rhizen Pharmaceuticals AG Inhibitors of poly(adp-ribose) polymerase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3813531A1 (de) * 1987-05-02 1988-11-10 Asta Pharma Ag Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
ZA882639B (en) * 1987-05-02 1988-09-30 Asta-Pharma Aktiengesellschaft New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives
KR100804564B1 (ko) * 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
EP1397350B1 (en) * 2001-05-08 2007-02-28 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
IL163562A0 (en) * 2002-02-19 2005-12-18 Ono Pharmaceutical Co fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos

Also Published As

Publication number Publication date
KR20070057859A (ko) 2007-06-07
CA2577191A1 (en) 2006-03-02
JP2008510783A (ja) 2008-04-10
IL181408A0 (en) 2007-07-04
BRPI0514632A (pt) 2008-06-17
MX2007002318A (es) 2007-04-17
WO2006021801A1 (en) 2006-03-02
EP1791827A1 (en) 2007-06-06
AU2005276229A1 (en) 2006-03-02
NZ553979A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
NO20071579L (no) 4-Heteroarylmetylsubstituerte ftalazinonderivater
LU92680I2 (fr) Olaparib ainsi que des sels et des solvates de celui-ci
MEP14208A (en) Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
TNSN05212A1 (en) Phthalazinone derivatives
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
MA31953B1 (fr) Nouveaux derives du thiophene.
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
NO20066055L (no) Pyridinderivater
TW200833675A (en) Nicotinamide derivatives
EP3812372A3 (en) 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases
UA102574C2 (ru) 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
MX2009011212A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
TW200833340A (en) Imidazo [1, 2-b] pyridazine derivatives
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201070839A1 (ru) Новые производные ацилцианопирролидинов
ME00961B (me) Derivati-7 alkinil-1,8-naftiridoni, njihova priprema i njihova primjena u liječenju
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
GEP20146063B (en) Solid pharmaceutical composition
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application